Abstract. The unique bioenergetic feature of cancer, aerobic glycolysis or the Warburg effect, is an attractive therapeutic target for cancer therapy. Reversing the glycolytic phenotype may trigger apoptosis in tumor cells. Recently, dichloroacetate (DCA) was proven to produce significant cytotoxic effects in certain tumor cells through this distinct mechanism. In this study, the effect of DCA on the metabolism of cervical cancer HeLa cells was explored and its synergistic growth inhibition with cisplatin was also evaluated. The intracellular changes in HeLa cells following DCA exposure were analyzed through cell viability, intracellular H 2 O 2 and pH levels, mitochondrial membrane potential (MMP), expression of apoptotic proteins and Kv1.5 channel, and intracellular-free Ca 2+ concentration ([Ca 2+ ] i ). For the evaluation of combination chemotherapy, HeLa cells were treated with a combination of DCA and cisplatin at various concentrations for 48 h. Cell viability was determined by CCK-8 assay and the synergy of the two agents was evaluated using the R index method. DCA shifted the metabolism of HeLa cells from aerobic glycolysis to glucose oxidation as shown by the increased intracellular H 2 O 2 and pH levels. The change of the metabolism modality led to a drop in MMP and the increase of apoptotic proteins (caspase 3 and 9). The increased Kv1.5 expression and decreased [Ca 2+ ] i established a positive feedback loop that resulted in reduced tonic inhibition of caspases. Combination chemotherapy of DCA and cisplatin exhibited a significant synergy in inhibiting the proliferation of HeLa cells. The specific apoptotic mechanism of DCA as distinguished from the cisplatin may be partly responsible for the synergy and further in vivo study on combination chemotherapy of the two agents in cervical cancer xenografts in mice is warranted.
Introduction
Cervical cancer is the second most common cancer among women, with an estimated worldwide burden of 493,000 new cases and 274,000 deaths each year (1) . Nowadays, there are two inspiring landmarks in the battle against cervical cancer. The first is the development of the Papanicolaou smear in 1943 which made possible the screening and early detection of the disease (2) . The second is the prevention of cervical dysplasia using the human papillomavirus (HPV) vaccine (Gardasil ® ) approved by FDA in 2006 (3, 4) . Despite these advances, nearly one-third of patients with invasive cervical cancer die from recurrent or metastatic disease and the management of invasive cervical cancer still remains a clinical challenge. Systematic chemotherapy is the major treatment modality for invasive cervical cancer, although in most circumstances it is limited to palliative management. Until recently, ~60 cytotoxic agents have been tested in cervical cancer (5) , among them cisplatin, a drug that can bind to and cause crosslinking of DNA and ultimately trigger apoptosis in tumor cells, has consistently proven to be the most effective single anticancer drug against the recurrent or metastatic cervical cancer (5-7). However, the response rate of cisplatin treatment is not satisfactory, and the response is usually accompanied by high rates of toxicity such as nephrotoxicity, neurotoxicity and severe nausea and vomiting. Moreover, the majority of cancer patients will eventually relapse with cisplatin-resistant disease. Thus more effective and less toxic chemotherapy strategies for this disease are urgently required.
Recently, the unique bioenergetic feature of cancer, aerobic glycolysis or the Warburg effect, has received great attention as a potential therapeutic target in cancer therapy (8, 9) . Most cancer cells exhibit increased glycolysis and utilize this metabolic pathway for ATP generation as their main source of their energy supply despite an available oxygen source. This glycolytic phenotype is closely associated with the state of apoptosis resistance, and reversing this cytoplasm-based glycolysis to the mitochondria-based glucose oxidation may trigger apoptosis in tumor cells (10) (11) (12) (13) (14) . The key regulator of cellular glucose oxidation metabolism is pyruvate dehydrogenase (PDH) which is inhibited by pyruvate dehydrogenase kinase (PDK) in most tumor cells. Bonnet et al firstly found that dichloroacetate (DCA), a small molecule and a well-characterized inhibitor of PDK that has been used for more than 30 years in the treatment of lactic acidosis, could significantly inhibit the PDK activity in tumor cells and promote apoptosis in lung, breast and glioblastoma cancer cells. DCA also inhibited the growth of subcutaneously implanted A549 tumors in athymic rats without observable toxicity (10) . DCA could also sensitize both wildtype and overexpressing Bcl-2 human prostate cancer cells to radiation in vitro (15) . A recent study by Michelakis et al proved that DCA could exhibit clinical antitumor efficacy in patients with glioblastoma and the dose-limiting toxicity was a dose-dependent, reversible peripheral neuropathy, and there was no hematologic, hepatic, renal, or cardiac toxicity (16) .
Based on these inspiring results, and the fact that this distinctive metabolism has not been targeted by classical chemotherapeutics, we hypothesized that DCA may be cytotoxic to cervical cancer cells and exhibit synergistic effects with cisplatin. This might allow the use of lower concentration of cisplatin and might potentially decrease the cisplatin-associated side-effects in chemotherapy. In the present study, we determined the in vitro cytotoxicity of DCA and explored the underlying mechanisms it uses against cervical cancer HeLa cells, and assessed the potential synergism of DCA and cisplatin in inhibiting the growth of HeLa cells.
Materials and methods
Reagents. Dichloroacetate (sodium salt, DCA), cisplatin, rotenone, DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid disodium salt), 4-aminopyridine (4-AP), t-butyl-H 2 O 2 (tert-butyl hydro-peroxide), DAPI (4',6'-diamidino-2-phenylindole dihydrochloride), and cleaved caspase 3 antibody were purchased from Sigma-Aldrich (St. Louis, MO, USA). Amplex Red, SNARF-1/AM (seminaphtorhodafluor-1-acetoxymethylester), MitoTracker Red, Fluo-3/AM and Hoechst 33342 were obtained from Molecular Probes (Eugene, OR, USA). VIVIT (NFAT inhibitor) was from Calbiochem (San Diego, CA, USA). Goat anti-rabbit IgG-TR, goat antimouse IgG-FITC, Kv1.5 (H-120) and actin antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against caspase 3, caspase 9 and cleaved caspase 9 were obtained from Cell Signaling Technology (Danvers, MA, USA)
Cell culture. HeLa (cervix adenocarcinoma, CCL-2) and HUVEC (human umbilical vein endothelial cells, CRL-1730) cell lines were obtained from the American Type Culture Collection (Manassas, VA) and routinely maintained in our lab. HeLa cells and HUVEC were maintained in Dulbecco's modified Eagle's medium (DMEM) and DMEM/F1, respectively, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U penicillin/ml and 100 μg streptomycin/ml in a humidified atmosphere of 5% CO 2 at 37˚C. Intracellular pH assay. The SNARF-1/AM, a pH-sensitive fluoroprobe, was used to measure intracellular pH (10) . In brief, HeLa cells were cultured on sterile glass coverslips in 24-well plates (5x10 4 cells/well). After 24 h incubation, the cells were treated with and without DCA (8 mM) for 48 h. Then the cells were loaded with 5 μM SNARF-1/AM for 45 min (37˚C) and washed with PBS for 30 min (37˚C). After that, Hoechst 33342 (1 μM) was used to stain nuclei for 10 min. Fluorescence was measured at 560 nm with excitation at 543 nm.
Mitochondrial membrane potential assessment. Mitochondrial membrane potential (MMP) was measured on the ArrayScan high content screening (HCS) system (Cellomics, Inc., Pittsburgh, PA, USA) (18) . In brief, 5x10 3 HeLa cells per well were seeded into 96-well plates. After 24 h incubation, the cells were treated with DCA (8 mM) at 37˚C for 48 h. As control, HeLa cells were pretreated with DIDS (0.5 mM), an inhibitor of the mitochondrial voltage-dependent anion channel (VDAC), for 10 min before exposure under DCA (19) . Then 50 μl of the MitoTracker/Hoechst solution (Cellomics Inc.) was added and the cells were incubated for 30 min at 37˚C. Fixation solution (100 μl) was added directly to each well without removing the medium and the cells were incubated in a fume hood at room temperature for 10 min. The wells were aspirated and the plate was washed once with 200 μl of wash buffer-M. The plate was sealed and run on the ArrayScan HCS System. The intensity of red fluorescence represented the MMP of the cells. All MMP assessments were performed in triplicate. (20) . In brief, 5x10 4 cells per well were cultured on sterile glass coverslips in 24-well plates. After 24 h incubation, the cell was exposed to different treatments, and then were loaded with 5 μM Fluo-3/AM for 45 min (37˚C) and washed for 30 min in PBS (37˚C) to allow cleavage of the acetoxymethyl esters. Then Hoechst 33342 (1 μM) was used to stain nuclei for 10 min. Fluorescence of intracellular free Ca 2+ was measured at 525 nm with excitation at 488 nm.
Combination chemotherapy analysis. In combination chemotherapy experiments, the cells were concurrently treated with various concentrations of cisplatin (0.5, 1, 2, 4, 8, 16 μM) and DCA (2, 4, 8 and 16 mM) for 48 h. Then CCK-8 agent was added and incubated for 2 h at 37˚C for color development. Cell viability was obtained using the method mentioned above. The nature of the interaction between DCA and cisplatin was determined by calculating the R index (RI) as described by Kern (21) and modified by Romanelli (22) The RI value is obtained as a ratio of the expected cell survival (S exp , defined as the product of the survival observed with drug A alone and the survival observed with drug B alone) to the observed cell survival (S obs ) for the combination of A and B (RI= S exp /S obs ). RI of 1 (additive effect) or lower indicates the absence of synergism. Synergism is then defined as RI of greater than unity. To further assess the statistical significance of the interactions, we performed one-sample t-test using the additive model based on the null hypothesis that there was no synergistic interaction between the two agents. Three-dimensional response surface graph of RI as a function of the concentrations of DCA and cisplatin were delineated using Statistica 6.0 software (StatSoft Inc., Tulsa, USA).
Statistical analysis. The data are presented as the mean ± SD. Inter-group differences were assessed by Student's t-test or ANOVA with a follow-up LSD test using the SPSS 11.0 software. P<0.05 indicated a significant difference.
Results
Effects of DCA on the viability of HeLa cells. HeLa cells were exposed to increasing concentrations of DCA to determine the effect of the agent on cell viability. The results showed that DCA reduced the viability of HeLa cells in a dosedependent manner after 48 h treatment and exerted significant cytotoxicity at a concentration of above 4 mM (Fig. 1) . 
Influence of DCA on H 2 O 2 production and pH in HeLa cells.
After 1 h incubation, 8 mM DCA significantly increased H 2 O 2 production in HeLa cells by 70% (P<0.01) and this increase could be completely inhibited by 0.5 μM rotenone (Fig. 2) . Rotenone is an inhibitor of the mitochondrial electron transport chain (ETC) complex I, which is a critical component of oxidative phosphorylation. The results suggested that DCA-induced increase of H 2 O 2 production in HeLa cells was achieved through promoting oxidative phosphorylation. The intracellular fluorescence intensity of SNARF-1/AM represented the intracellular pH value. It showed that DCA (8 mM) treatment for 48 h increased the intracellular pH value, with a fluorescence intensity five times that of untreated HeLa cells (P<0.01) (Fig. 3) . This phenomenon could be due to increased oxidative phosphorylation (Fig. 2) and decreased lactate production from aerobic glycolysis. (Fig. 4) , while it had no effect on the MMP of noncancerous HUVEC (data not shown). The DCA-induced significant drop of MMP in HeLa cells could be completely inhibited by DIDS (Fig. 4) , an inhibitor of the mitochondrial VDAC, which is a critical component of the mitochondrial transition pore (MTP). DCA (8 mM) treatment for 48 h induced a significant increase in the expression of both caspase 3 and caspase 9, including both inactive and active sections, in HeLa cells (Fig. 5) . These results proved that DCA induced apoptosis of HeLa cells through a mitochondria-regulated mechanism.
Effect of DCA on MMP and apoptosis-associated proteins in
Influence of DCA on Kv1.5 expression and intracellular calcium levels in HeLa cells. The CLSM images showed that treatment with 8 mM DCA for 48 h induced higher expression of Kv1.5 in HeLa cells compared with the control cells (Fig. 6) , which was consistent with the results of Western blot assays (Fig. 5) . As expected, t-butyryl-H 2 O 2 , which mimicked the DCA-induced H 2 O 2 , and VIVIT, which is an inhibitor of NFAT that could translocate into the nucleus and decrease Kv1.5 expression, also increased Kv1.5 expression (Fig. 6 ). The intracellular free Ca 2+ concentration ([Ca 2+ ] i ) was detected using the Fluo-3/AM fluorescence probe (Fig. 7) Effect of combination chemotherapy of DCA and cisplatin on the viability of HeLa cells. First, the effect of cisplatin alone on the viability of HeLa cells was examined. The results showed that cisplatin dose-dependently reduced cell viability in the concentration range from 0.5 to 16 μM after 48 h treatment and started to display obviously cytocidal efficacy at the concentration of 1 μM (Fig. 8a) . For the evaluation of combination chemotherapy, HeLa cells were treated in culture with a combination of DCA and cisplatin at various concentrations for 48 h. Cell viability was determined by CCK-8 assay and the synergy of the two agents was evaluated using the R index method. The combination of DCA and cisplatin at certain drug concentrations led to remarkable synergistic effect in decreasing the (Fig. 8b) . At a DCA concentration of 16 mM, synergy was clearly observed at a cisplatin concentration of higher than 4 μM and the RI value reached 1.6 with cisplatin concentration of 16 μM (P<0.01). In contrast, no synergistic interaction was observed when the cells were treated with DCA at the low concentration of 2 mM (P>0.05). A three-dimensional response surface plot (Fig. 9) visually depicts the synergistic effect of DCA and cisplatin in decreasing the viability of HeLa cells, showing that the RI values increased with the concentration of either DCA or cisplatin.
Discussion
DCA dose-dependently reduced the viability of HeLa cells (Fig. 1) exposed to DCA (23) . In this study, we further found that intracellular H 2 O 2 production was significantly increased after HeLa cells were treated by DCA for 1 h, and this was almost completely inhibited by rotenone, an inhibitor of mitochondrial electron transport chain complex I (Fig. 2) . Meanwhile, 48 h of DCA significantly increased the intracellular pH of HeLa cells (Fig. 3) . It is known that HeLa cells largely rely on aerobic glycolysis for their ATP budget (24) .
The results indicate that DCA may shift the metabolism of HeLa cells from glycolysis back to glucose oxidation. The enhanced glucose oxidation led to sustained release of H 2 O 2 (reactive oxygen species, ROS), which could inhibit the mitochondrial H + efflux and ultimately decrease the MMP (Fig. 4) . The drop of MMP was almost completely inhibited by DIDS, an inhibitor of the VDAC, which is an important component of the mitochondrial transition pore (MTP). The opening of the MTP by DCA allowed the efflux of cytochrome c and apoptosis inducing factors, activated caspases 3 and 9 ( Fig. 5) , and decreased cell viability through apoptosis (Fig. 1) .
Moreover, DCA treatment remarkably increased the expression of Kv1.5 which could be attributed to the increased H 2 O 2 production as mimicked by t-butyryl-H 2 O 2 (Fig. 6) . The enhanced expression of Kv1.5 in the plasma membrane decreased the intracellular K + concentration ([K + ] i ) and thus led to reduced tonic inhibition of caspases (10, 12) . On the other hand, K + efflux hyperpolarized the cells and inhibited the voltage-dependent Ca 2+ entry (Fig. 7) . The decreased [Ca 2+ ] i inhibited the activation of NFAT and its translocation into the nucleus, thus further increasing Kv1.5 expression, establishing a positive feedback loop. Taken together, DCA shifted the metabolism of HeLa cells from aerobic glycolysis to glucose oxidation and induced cell apoptosis by depolarizing mitochondria and activating/upregulating Kv1.5.
For recurrent or metastatic cervical cancer, intravenous infusion of 50 mg/m 2 cisplatin at 3-week intervals has been adopted by the oncology community as the standard regimen since 1986. But in subsequent trials, single-agent cisplatin used as the control arm showed a response rate of only 13-19%, a progression-free survival of 2.8-3.2 months, and an overall survival of only 6.5-8.8 months (5). The efficacy of singleagent cisplatin is still not satisfactory, though it is superior to 21 other known cytotoxic agents that have activity against cervical cancer. The combined-agent chemotherapy regimens based on cisplatin have been widely evaluated in clinical trials for improved efficacy. However, until recently, only the combination of cisplatin and topotecan has improved overall survival. In this study, DCA, a drug that can target the unique tumor metabolism Warburg effect, shift the aerobic glycolysis to glucose oxidation, and induce tumor cell apoptosis, was combined with cisplatin for cervical cancer cell chemotherapy for the first time.
A variety of in vitro assays and different mathematics models have been developed to investigate cytotoxic effects and to analyze the type of drug interactions in combination chemotherapy (25) . In the present study, the improved sensitivity of HeLa cervical cancer cells to the combination chemotherapy was evaluated using the RI method. This method was adopted because treatment with DCA alone had a relatively low effect on cell viability compared with cisplatin ( Fig. 1) , so other methods, such as the median effect principle and isobologram methods, were not suitable (26, 27) . In this study, DCA exhibited significant synergistic interactions with cisplatin in decreasing the viability of HeLa cells with an increase of the drug concentration (Figs. 8 and 9 ). It should be noted that Dhar et al have developed a new compound, mitaplatin, which contains two DCA units and one platinum center (28) . The cytotoxicity of mitaplatin is only comparable to that of cisplatin, although in a variety of cancer cell lines it equals or exceeds that of all known Pt(IV) compounds. We speculate that the fixed intracellular molar ratio of platinum and DCA (1:2) after the reduction of mitaplatin in cancer cells may not be the optimal combination of the two agents for cancer cell killing. When they were independently dosed as such in present study, the synergism of the two agents could be revealed and optimized. Cisplatin and DCA should have different potentials of penetrating cell plasma, thus the exact intracellular concentrations and molar ratio of the two agents in synergism remain to be determined.
Cisplatin is one of the most potent compounds and it has been used in cancer chemotherapy for more than 30 years as the first line drug in cervical cancer therapy, although its biochemical mechanism of action is still not fully elucidated. The accepted theory is that cisplatin induces its cytotoxic properties through binding to nuclear DNA and thereby interfering with normal transcription and/or DNA replication mechanisms (29, 30) . Several lines of evidence support that the cytotoxic effects induced by binding of cisplatin to non-DNA targets (especially proteins) may also contribute to its action (29, 30) . The sensitive cancer cells attacked by cisplatin finally die through apoptosis or necrosis, dependent on factors such as the availability of energy and the metabolic condition of the cell (30) . We postulate that the specific apoptotic mechanism of DCA as distinguished from the cisplatin may be partly responsible for their synergistic cytocidal effect in HeLa cells. An in vivo study is now being undertaken in our laboratory to evaluate the synergistic effect in inhibiting the growth of tumor xenografts in mice, and we are also trying to identify potential predictive biomarkers with respect to the drug interaction.
